PRIMARY PREVENTION

HPV VACCINE

Teknologi Vaksin HPV

Empty Shell formed by
recombinant biotechnology
to mimic the viral 3D shape.
Does not contain
infectious DNA

Vaccine

Real
Virus

Does not contain mercury

(thimerosal)
GARDASIL is a trademark of Merck & Co., Inc., Whitehouse Station, NJ, USA.
*VLP = Virus-like particle.
1. Villa LL, Costa RL, Petta CA, et al. Lancet Oncol. 2005;6:271278.

Image courtesy of Dr. Ian Frazer

ID/CER/0015/13 AD 26/07/13 ED 26/07/2015

Mekanisme perlindungan vaksin

HPV
3. Infeksi baru dicegah
2. Infeksi pada tempat
lain dicegah

IgG antibodies

1. Turunnya virus
setelah tumpahan

Adapted from Schwarz TF & Leo O. Gynecol Oncol 2008; 110: S

PROPHYLACTIC VACCINE

Antigens

AS04 adjuvant

+
HPV 16 VLPs

Aluminium
salt
(Al(OH)3)

MPL
Immunostimulant

HPV 18 VLPs

AS04-containing vaccine

QUADRIVALENT
Antigens

Adjuvant

+
HPV 16 VLPs

HPV 18 VLPs

HPV 6 VLPs

HPV 11 VLPs

Aluminium
Aluminium salt
salt

(amorphous
(amorphous
aluminium
aluminium
hydroxyphosphate
hydroxyphosphate
sulphate
sulphate [AAHS])
[AAHS])

AAHS-containing vaccine

PEMBERIAN VAKSIN
Recommended schedule
Intramuscular injection (IM)

BIVALENT

0
Dosis
1

QUADRIVALENT

1
Dosis
2

6
Dosis
3

Phase III study vs. HAV (PATRICIA): 3 years

BIVALENT efficacy against CIN regardless of

HPV type in lesion
Young women
before sexual
debut, 1 dose

(TVC-nave)
Estimated
prevalence
HPV 16/18

Endpoint

Vaccine

Placebo

N = 5,449

N = 5,436

95 % CI

Vaccine efficacy1

P-value

2530 %2

CIN1+

106

211

50.1

35.961.4

<0.0001

52%3

CIN2+

33

110

70.2

54.780.9

<0.0001

up to 70%4

CIN3+

23

87.0

54.997.7

<0.0001

CIN 3+

93.2

78.998.7

End of study of PATRICIA5

1.Paavonen J, et al. Lancet 2009; 374:301314; 2. Clifford GM, et al. Cancer Epi Biom. Prev 2005; 14:11571164; 3. Smith JS, et
al. Int J Cancer 2007; 121:621632; 4. Cervical cancer data. Available at: www.who.int/hpvcentre/statistics (Accessed 1 May
2009); 5. Paavonen J, et al. 26th IPvC, Montreal, 3-8 July 2010, abstract 689.

Vaccine Efficacy
Per-Protocol Efficacy Population - Protocols 007, 013, 015
(n=18780)
Quadrivalen
HPV
%
t
6/11/16/18Placebo
95% CI
Efficacy
Related
Vaccine
CIN 2/3 or
AIS

73

99

92, 100

Vulval and
Vaginal
Lesions (incl.
Genital
Warts)

189

99

96, 100

VIN 2/3 or
VaIN 2/3

15

100

72, 100

PP = received 3 vaccinations within 1 year; no major protocol violations; HPV 16/18 sero(-) at day 1 and HPV
16/18 DNA(-) day 1 to month 7; cases counted starting after month 7. CIN = cervical intraepithelial neoplasia;
AIS = adenocarcinoma in situ.

Average follow up for 3 years

Guidelines for HPV Vaccination

Its our responsibility to

protect our patients

INDONESIAN HPV VACCINE GUIDELINE

PROPHYLACTIC VACCINE
IM DELTOID MUSCLE
0,1-2,6
0-6

10-55 YEARS OLD

SEXUAL (-)

LACTATION

HPV VACCINE
SEXUAL (+)
PAP SMEAR (-)

NO PREGNANCY
PRECANCER LESION
IN THE PAST
NO HPV INFECTION

HPV INFECTION
IN THE PAST
NO PRECANCER LESION

VACCINATION + PAP SMEAR

POGI (HOGI)-IDAI

SPECIFIC DOSE

MALE HPV VACCINE

Program Vaksinasi Nasional

HOGI mengakselerasi program
nasional vaksinasi
Program vaksinasi nasional ditujukan
pada anak perempuan usia 12 tahun
ATAU kelas 6 Sekolah Dasar dengan
pemberian 2 dosis

RINGKASAN
KANKER SERVIKS
MERUPAKAN SALAH
SATU MASALAH DALAM
KESEHATAN
KANKER SERVIKS
DAPAT DICEGAH
VAKSIN HPV
MERUPAKAN
PENCEGAHAN PRIMER